FIRST & ONLY
IL-23i for Crohn's that can deliver
CLINICAL REMISSION
&
ENDOSCOPIC IMPROVEMENT
IL-23 inhibitor (IL-23i) with clinical remission and endoscopic response co-primary measures in label at both 12 and 52 weeks.
Learn how AbbVie could help you save on SKYRIZI.
Call 1.866.SKYRIZI or click tap to learn more ▸
IL-23 inhibitor (IL-23i) with clinical remission and endoscopic response co-primary measures in label at both 12 and 52 weeks.
Learn how SKYRIZI helps people with Crohn's achieve symptom relief, long-lasting remission at 1 year, and endoscopic improvement.
After 3 Starter Doses
Make SKYRIZI part of your routine with at-home dosing every 8 weeks, after a total of 3 starter doses through a vein in the arm (intravenous infusion) and proper training from your healthcare professional.
Get more information and resources sent directly to you.
Your Skyrizi Complete Nurse Ambassador is committed to getting to know you and your individual SKYRIZI needs.
Get to Know the Nurse Ambassador
*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.
Already taking SKYRIZI? Share your experience with SKYRIZI to help inform and inspire others. To participate, please email us at info@SPEAKnetwork.net or call 888-298-8269.
Get information to help you talk to your doctor about Crohn’s—and learn how SKYRIZI can help.
Download the BrochureSKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems in Crohn's disease: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
SKYRIZI is a prescription medicine used to treat adults with:
US-SKZ-220579
Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.
Legal Notices/Privacy Policy. Copyright 2023, AbbVie Inc., North Chicago, Illinois, U.S.A. If you have any questions about AbbVie’s SKYRIZI.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
US-SKZ-220373
US-SKZ-220373
US-SKZ-220001